Τίτλος:	Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease
Δημιουργός:	Wallentin L
Συντελεστής:	Μέλος ερευνητικής ομάδας: Manolis AJ
Χρονολογία:	2016
Γλώσσα:	Αγγλικά
Εξειδίκευση τύπου :	Άρθρο
Περιγραφή:	J Am Heart Assoc. 2016 Jun 21;5(6). pii: e003407
Περίληψη:	BACKGROUND: We evaluated lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in patients with stable coronary heart disease before and during treatment with darapladib, a selective Lp-PLA2 inhibitor, in relation to outcomes and the effects of darapladib in the STABILITY trial. METHODS AND RESULTS: Plasma Lp-PLA2 activity was determined at baseline (n=14 500); at 1 month (n=13 709); serially (n=100) at 3, 6, and 18 months; and at the end of treatment. Adjusted Cox regression models evaluated associations between Lp-PLA2 activity levels and outcomes. At baseline, the median Lp-PLA2 level was 172.4 μmol/min per liter (interquartile range 143.1-204.2 μmol/min per liter). Comparing the highest and lowest Lp-PLA2 quartile groups, the hazard ratios were 1.50 (95% CI 1.23-1.82) for the primary composite end point (cardiovascular death, myocardial infarction, or stroke), 1.95 (95% CI 1.29-2.93) for hospitalization for heart failure, 1.42 (1.07-1.89) for cardiovascular death, and 1.37 (1.03-1.81) for myocardial infarction after adjustment for baseline characteristics, standard laboratory variables, and other prognostic biomarkers. Treatment with darapladib led to a ≈65% persistent reduction in median Lp-PLA2 activity. There were no associations between on-treatment Lp-PLA2 activity or changes of Lp-PLA2 activity and outcomes, and there were no significant interactions between baseline and on-treatment Lp-PLA2 activity or changes in Lp-PLA2 activity levels and the effects of darapladib on outcomes. CONCLUSIONS: Although high Lp-PLA2 activity was associated with increased risk of cardiovascular events, pharmacological lowering of Lp-PLA2 activity by ≈65% did not significantly reduce cardiovascular events in patients with stable coronary heart disease, regardless of the baseline level or the magnitude of change of Lp-PLA2 activity. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00799903. © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. KEYWORDS: lipoprotein;
Θέμα:	Atherosclerosis Αθηροσκλήρωση Coronary Disease Στεφανιαία Νόσος Inflammation Φλεγμονή Myocardial Infarction Έμφραγμα Μυοκαρδίου Lipoproteins Λιποπρωτεΐνες
Εναλλακτικός δικτυακός τόπος:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937279/pdf/JAH3-5-e003407.pdf
Άδεια Χρήσης:	Αναφορά Μη Εμπορική Χρήση Παρόμοια Δανομή
Διάθεση ψηφιακού τεκμηρίου:	Πλήρης
Εμφανίζεται στις Ομάδες Τεκμηρίων:	Καρδιολογία

Εξαγωγή σε:

Επιλέξτε στυλ βιβλιογραφικής αναφοράς APA - American Psychological Association Harvard